Javascript must be enabled to continue!
Oxycodone target concentration dosing for acute pain in children
View through CrossRef
AbstractBackgroundOxycodone pharmacokinetics have been described in premature neonates through to obese adults. Covariate influences have been accounted for using allometry (size) and maturation of oxycodone clearance with age. The target concentration is dependent on pain intensity that may differ over pain duration or between individuals.MethodsWe assumed a target concentration of 35 mcg.L−1 (acceptable range ±20%) to be associated with adequate analgesia without increased risk of adverse effects from respiratory depression. Pharmacokinetic simulation was used to estimate dose in neonates through to obese adults given intravenous or parenteral oxycodone.ResultsThere were 84% of simulated oxycodone concentrations within the acceptable range during maintenance dosing. Variability around the simulated target concentration decreased with age.The maturation of oxycodone clearance is reflected in changes to context‐sensitive halftime where clearance is immature in neonates compared with older children and adults. The intravenous loading and maintenance doses for a typical 5‐year‐old child are 100 mcg.kg−1 and 33 mcg.kg−1.h−1. In a typical adult, the loading dose is 100 mcg.kg−1 and maintenance dose 23 mcg.kg−1.h−1.ConclusionSimulation was used to suggest loading and maintenance doses to attain an oxycodone concentration of 35 mcg.L−1 predicted in adults. Although the covariates age and weight contribute 92% variability for clearance, there remains variability accounting for 16% of concentrations outside the target range. Duration of analgesic effect after ceasing infusion is anticipated to be longer in neonates where context‐sensitive halftime is greater than older children and adults.
Title: Oxycodone target concentration dosing for acute pain in children
Description:
AbstractBackgroundOxycodone pharmacokinetics have been described in premature neonates through to obese adults.
Covariate influences have been accounted for using allometry (size) and maturation of oxycodone clearance with age.
The target concentration is dependent on pain intensity that may differ over pain duration or between individuals.
MethodsWe assumed a target concentration of 35 mcg.
L−1 (acceptable range ±20%) to be associated with adequate analgesia without increased risk of adverse effects from respiratory depression.
Pharmacokinetic simulation was used to estimate dose in neonates through to obese adults given intravenous or parenteral oxycodone.
ResultsThere were 84% of simulated oxycodone concentrations within the acceptable range during maintenance dosing.
Variability around the simulated target concentration decreased with age.
The maturation of oxycodone clearance is reflected in changes to context‐sensitive halftime where clearance is immature in neonates compared with older children and adults.
The intravenous loading and maintenance doses for a typical 5‐year‐old child are 100 mcg.
kg−1 and 33 mcg.
kg−1.
h−1.
In a typical adult, the loading dose is 100 mcg.
kg−1 and maintenance dose 23 mcg.
kg−1.
h−1.
ConclusionSimulation was used to suggest loading and maintenance doses to attain an oxycodone concentration of 35 mcg.
L−1 predicted in adults.
Although the covariates age and weight contribute 92% variability for clearance, there remains variability accounting for 16% of concentrations outside the target range.
Duration of analgesic effect after ceasing infusion is anticipated to be longer in neonates where context‐sensitive halftime is greater than older children and adults.
Related Results
Monitoring oxycodone use in patients with chronic pain: Analysis of oxycodone and metabolite excretion in saliva and urine
Monitoring oxycodone use in patients with chronic pain: Analysis of oxycodone and metabolite excretion in saliva and urine
Objective: Saliva is purported to have a close correspondence to plasma concentrations due to a passive diffusion process from plasma to saliva. However, limited data are available...
Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Abstract
Thoracic outlet syndrome (TOS) is a complex and often overlooked condition caused by the compression of neurovascular structures as they pass through the thoracic outlet. ...
Oxycodone 5 Miligram is More Effective Than Ketorolac 30 Miligram in Suppressing Cortisol Levels During General Anesthesia
Oxycodone 5 Miligram is More Effective Than Ketorolac 30 Miligram in Suppressing Cortisol Levels During General Anesthesia
Background: Preemptive analgesia is a developing clinical concept, which involves administering analgesics before pain stimulation occurs, to prevent the sensitization of the nervo...
Decreased responsiveness to oxycodone: A case of a pharmacokinetic drug interaction?
Decreased responsiveness to oxycodone: A case of a pharmacokinetic drug interaction?
Concurrent administration of oxycodone and phenytoin may cause, through induction of CYP3A4 enzymes, decreased analgesic effects of oxycodone. However, no descriptions of this inte...
Oxycodone hydrochloride controlled‐release tablets (OxyContin®): post‐marketing surveillance (PMS) study for relieving moderate to severe non‐cancer pain
Oxycodone hydrochloride controlled‐release tablets (OxyContin®): post‐marketing surveillance (PMS) study for relieving moderate to severe non‐cancer pain
Objective: To evaluate the efficacy and safety of oxycodone hydrochloride controlled‐release (CR) tablets (Oxycontin®, Mundipharma International Limited, Cambridge, UK), 5 mg, 10 m...
Exploring the Efficacy of Once and Twice Weekly Thyroxine Dosing: A Promising Approach for Hypothyroidism Management
Exploring the Efficacy of Once and Twice Weekly Thyroxine Dosing: A Promising Approach for Hypothyroidism Management
Abstract
Introduction
Hypothyroidism is a common endocrine disorder, in which the management involves daily intake of thyroxine. However, adherence to a daily medication regimen po...
Use of Extended Dosing Intervals of Dupilumab in Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis
Use of Extended Dosing Intervals of Dupilumab in Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis
Abstract:
Dupilumab is a biological agent used in atopic dermatitis (AD) with 2-weekly dosing. Extending dosing inte...
Chest Wall Hydatid Cysts: A Systematic Review
Chest Wall Hydatid Cysts: A Systematic Review
Abstract
Introduction
Given the rarity of chest wall hydatid disease, information on this condition is primarily drawn from case reports. Hence, this study systematically reviews t...

